Clinical Trial

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid tumors. It is necessary to collect clinical data points and treatment outcomes in order to demonstrate clinical validity for longitudinal monitoring with ctDNA and correlation of ctDNA dynamics with therapeutic response, as evaluated by standard methods, including RECIST 1.1 and CT scan measurements.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-06-29; most recent amendment 2025-08-18.
Status change: Not Yet Recruiting → Recruiting 2023-11-17
Trial Details
NCT Number NCT05935384
Lead Sponsor Guardant Health, Inc.
Conditions Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Enrollment 470 participants
Start Date 2023-10-25
Primary Completion 2030-12-30 (estimated)
Study Completion 2030-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-22